Zinzino Sales Surge Masks Regional Weakness in February
Event summary
- Zinzino group revenue increased by 32% year-over-year in February 2026, reaching SEK 286.3 million.
- Faun Pharma’s external sales rose by 24% to SEK 5.2 million.
- Year-to-date (January-February) revenue increased by 26% to SEK 568.6 million.
- Nordic and East European regions experienced revenue declines of 9% and 10% respectively in February.
- North and South American regions saw significant growth, with increases of 108% and 200% respectively.
The big picture
Zinzino’s strong overall revenue growth masks underlying regional vulnerabilities. The company’s reliance on emerging markets for a significant portion of its gains exposes it to currency fluctuations, political instability, and evolving consumer preferences. While the Faun Pharma acquisition appears to be contributing positively, its strategic fit and long-term value remain to be fully evaluated.
What we're watching
- Regional Disparities
- The contrasting performance between high-growth regions (North/South America) and declining regions (Nordics/East Europe) warrants further investigation into localized market conditions and Zinzino’s regional strategies.
- Faun Pharma Integration
- While Faun Pharma's sales are growing, the overall contribution remains small; the long-term strategic value of this subsidiary and its integration with Zinzino’s core business needs to be assessed.
- Sustainability
- Continued reliance on rapid growth in emerging markets like South America carries inherent risks; Zinzino must diversify its geographic footprint to ensure sustainable, long-term revenue generation.
Related topics